Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance
For the current fiscal year, the Company expects Group revenues in the range of
€760-800m (previously: € 840 - 880 m; 2024: € 797.0 m);
R&D expenditures are expected in a range of €40 - 50 m (unchanged; 2024: € 50.8 m);
Adjusted EBITDA is expected to reach €30-50m (unchanged; 2024: € 22.6 m).
The primary reasons for the refined guidance are a change in the revenue mix and significant cost savings in excess of initial targets set during the Priority Reset. Technology licensing - a key pillar of Evotec's strategic repositioning - is expected to make a stronger contribution. At the same time, the Shared R&D base business is expected to continue to operate in a challenging market environment in the second half of 2025. Group revenues were below expectations in H1 2025, while adjusted EBITDA was broadly in line with expectations. Actions are underway to transform the business towards sustainable profitable growth.
- End of the ad hoc release -
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
21 minutes ago
- Globe and Mail
Eagle Bancorp, Inc. (EGBN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Law Offices of Howard G. Smith continues its investigation on behalf of Eagle Bancorp, Inc. ('Eagle' or the 'Company') (NASDAQ: EGBN) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN EAGLE BANCORP, INC. (EGBN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On April 23, 2025, Eagle released its first quarter 2025 financial results, reporting net income of $1.7 million, compared to $15.3 million in the previous quarter, primarily due to 'a $14.1 million increase in provision expense, a $5.1 million decline in net interest income, and a $0.9 million increase in noninterest expenses.' The Company also stated that '[v]aluation risk in [its] office portfolio remains a concern and was the primary driver of the provision for credit losses.' On this news, Eagle's stock price fell $2.41, or 11.4%, to close at $18.78 per share on April 24, 2025, thereby injuring investors. Then, on July 23, 2025, Eagle released its second quarter 2025 financial results, reporting a $71.5 million decrease in net income from the prior quarter, due primarily to a $111.9 million increase in provision expense in order 'to resolve challenged loans and address related valuation pressures in the office portfolio.' On this news, Eagle's stock price fell as much as 22% during intraday trading on July 24, 2025, thereby injuring investors further. If you purchased Eagle securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith 3070 Bristol Pike, Suite 112 Bensalem, Pennsylvania 19020 Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Globe and Mail
21 minutes ago
- Globe and Mail
Securities Fraud Investigation Into Eagle Bancorp, Inc. (EGBN) Continues – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz continues its investigation of Eagle Bancorp, Inc. ('Eagle' or the 'Company') (NASDAQ: EGBN) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON EAGLE BANCORP, INC. (EGBN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On April 23, 2025, Eagle released its first quarter 2025 financial results, reporting net income of $1.7 million, compared to $15.3 million in the previous quarter, primarily due to 'a $14.1 million increase in provision expense, a $5.1 million decline in net interest income, and a $0.9 million increase in noninterest expenses.' The Company also stated that '[v]aluation risk in [its] office portfolio remains a concern and was the primary driver of the provision for credit losses.' On this news, Eagle's stock price fell $2.41, or 11.4%, to close at $18.78 per share on April 24, 2025, thereby injuring investors. Then, on July 23, 2025, Eagle released its second quarter 2025 financial results, reporting a $71.5 million decrease in net income from the prior quarter, due primarily to a $111.9 million increase in provision expense in order 'to resolve challenged loans and address related valuation pressures in the office portfolio.' On this news, Eagle's stock price fell as much as 22% during intraday trading on July 24, 2025, thereby injuring investors further. Contact Us To Participate or Learn More: If you purchased Eagle securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 Call us at: 310-914-5007 Email us at: info@ Visit our website at: Follow us for updates on Twitter at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Globe and Mail
21 minutes ago
- Globe and Mail
Law Offices of Howard G. Smith Encourages Neogen Corporation (NEOG) Investors To Inquire About Securities Fraud Class Action
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Neogen Corporation ('Neogen' or the 'Company') (NASDAQ: NEOG) common stock between January 5, 2023 through June 3, 2025, inclusive (the 'Class Period'). Neogen investors have until September 16, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NEOGEN CORPORATION (NEOG), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On January 10, 2025, Neogen disclosed that its second quarter GAAP net income was significantly negative due to a $461 million non-cash goodwill impairment charge related to its acquisition of the 3M Company ('3M'). The Company also revised its full year outlook, cutting revenue and EBITDA guidance. Further, the Company also revealed that as of November 30, 2024, it had material weaknesses in its internal control over financial reporting. On this news, Neogen's stock price fell $0.71, or 5.4%, to close at $12.36 per share on January 10, 2025, thereby injuring investors. Then, on April 9, 2025, Neogen disclosed that quarterly revenue had fallen 3.4% due, in part, to integration issues. The Company also further cut its full year revenue and EBITDA outlook and revealed that its CEO would be stepping down. On this news, Neogen's stock price fell $2.02, or 28.7%, to close at $5.02 per share on April 9, 2025. Then, on June 4, 2025, Neogen disclosed that, while its fourth quarter fiscal 2025 financial results would be 'materially approximate [to] where [the Company] had put [its] guide,' it 'would expect EBITDA margin to probably be around the high-teens' compared to the previous quarter's 22%. The Company explained that EBITDA margins would likely 'be in the low-20s, if not for the elevated inventory write-offs.' On this news, Neogen's stock price fell $1.04, or 17.3%, to close at $4.96 per share on June 4, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the integration with 3M was plagued with inefficiencies that Defendants knew would necessitate a goodwill impairment and would impact capital expenditures, revenues, and EBITDA margins; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you purchased Neogen common stock, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at:
